Last updated: October 25, 2026
RETISERT is a fluocinolone acetonide intravitreal implant marketed by Bausch + Lomb for chronic noninfectious posterior uveitis. FDA approval dates to 2005. Its commercial position has weakened because the implant requires an operating-room procedure, carries substantial cataract and intraocular-pressure risks, and competes with office-administered products including YUTIQ and OZURDEX. Bausch + Lomb does not separately report RETISERT revenue, so the product’s exact sales trajectory is unavailable from public filings. The key commercial issue is declining differentiation rather than near-term generic substitution.
What is RETISERT and how does it work?
RETISERT contains 0.59 mg of fluocinolone acetonide in a surgically implanted device. It releases corticosteroid into the vitreous over approximately 30 months and is indicated for chronic noninfectious posterior uveitis affecting the eye [1].
| Attribute |
RETISERT |
| Active ingredient |
Fluocinolone acetonide |
| Dosage form |
Intravitreal implant |
| Strength |
0.59 mg |
| FDA approval |
2005 |
| NDA |
021737 |
| Approved indication |
Chronic noninfectious posterior uveitis affecting the posterior segment of the eye |
| Administration |
Surgical implantation through a pars plana incision |
| Approximate treatment duration |
Up to 30 months |
| Marketing company |
Bausch + Lomb |
| Main clinical risks |
Cataract formation, elevated intraocular pressure, glaucoma, hypotony, endophthalmitis and retinal complications |
RETISERT’s pharmacologic value is sustained local steroid exposure. Its commercial limitation is the implantation procedure. The label warns that cataract surgery may be required in essentially all phakic eyes and that many patients require pressure-lowering treatment or glaucoma surgery [1].
When did RETISERT lose exclusivity?
RETISERT’s principal product-patent protection appears to have expired in the early 2020s, based on the public patent history associated with the implant technology. The product was approved in 2005, so any regulatory exclusivity associated with the original NDA expired long before current market competition emerged.
The practical loss of exclusivity did not automatically create a large generic market. RETISERT is a combination of an established corticosteroid and a specialized implant device. An abbreviated new drug application would need to address drug release, implant design, manufacturing controls, sterility and clinical equivalence. Those requirements are more complex than for an ordinary oral or ophthalmic solution.
RETISERT exclusivity timeline
| Year |
Event |
| 2005 |
FDA approved RETISERT for chronic noninfectious posterior uveitis [1] |
| 2010s |
Product remained a specialist treatment for severe or recurrent posterior uveitis |
| 2014 |
FDA approved ILUVIEN, another fluocinolone acetonide implant, for diabetic macular edema [2] |
| 2018 |
FDA approved YUTIQ for chronic noninfectious posterior uveitis [3] |
| Early 2020s |
Core RETISERT patent protection reached the end of its expected term |
| Current market |
Competition is driven more by alternative implants and corticosteroid delivery systems than by a clearly established generic RETISERT |
The current Orange Book status should be assessed against the FDA’s live Orange Book data. Public product materials do not support treating RETISERT as a product with meaningful remaining regulatory exclusivity. There is no basis to identify a current period of new chemical entity exclusivity, orphan exclusivity or pediatric exclusivity.
What patents protect RETISERT?
RETISERT’s original intellectual-property position centered on an intraocular implant capable of controlled corticosteroid release. The relevant protection covered implant construction, drug loading and sustained delivery rather than fluocinolone acetonide itself.
The commercial patent estate is weaker today for four reasons:
- Fluocinolone acetonide is an established active ingredient.
- The core implant technology has aged beyond the original launch period.
- Competing products use different implant sizes, release profiles and administration methods.
- A competitor can pursue a distinct device architecture rather than copy the original RETISERT design.
The most important residual barriers are manufacturing know-how and regulatory execution. A technically viable implant must maintain a reproducible release rate, remain sterile, avoid premature drug dumping and meet ophthalmic-device quality requirements.
How strong is the RETISERT patent estate?
RETISERT has a low-to-moderate current patent moat. The product had stronger protection during its launch period, but its commercial defense now depends on:
- Surgical familiarity among uveitis specialists.
- Physician confidence in long-duration steroid exposure.
- Patient selection for severe, recurrent disease.
- Manufacturing and sterile-implant expertise.
- Reimbursement and site-of-care economics.
- The difficulty of demonstrating equivalence for a controlled-release intraocular implant.
The patent estate is therefore less important than clinical positioning and procedural convenience. YUTIQ has reduced the strategic value of RETISERT’s long-duration profile by offering the same active ingredient in a smaller, office-administered implant.
What is the FDA regulatory status of RETISERT?
RETISERT remains an FDA-approved product for its original indication. Its label is materially narrower than the labels of several competing retinal corticosteroid products. FDA approval is for chronic noninfectious posterior uveitis involving the posterior segment, not for diabetic macular edema, retinal vein occlusion or broad inflammatory eye disease [1].
RETISERT is not a biologic. Biosimilar competition is therefore not applicable. A competing product would generally require an abbreviated or full drug application, depending on the extent to which the FDA accepts the proposed product as pharmaceutically and therapeutically equivalent.
The regulatory burden remains meaningful because local ocular delivery products are evaluated for:
- Dose uniformity.
- Drug-release kinetics.
- Implant integrity.
- Sterility and endotoxin control.
- Ocular tolerability.
- Intraocular-pressure effects.
- Surgical or injection-related complications.
How does RETISERT compare with YUTIQ and OZURDEX?
YUTIQ is RETISERT’s closest product competitor because both use fluocinolone acetonide for chronic noninfectious posterior uveitis. YUTIQ contains 0.18 mg and is injected in an office setting. Its label describes drug release for approximately 36 months [3].
OZURDEX uses dexamethasone in a biodegradable intravitreal implant. It is administered through an applicator rather than surgically sutured into the eye and has a shorter duration than RETISERT or YUTIQ. OZURDEX has broader use across retinal edema and inflammatory indications [4].
| Product |
Active ingredient |
Delivery |
Main uveitis positioning |
Commercial advantage |
| RETISERT |
Fluocinolone acetonide |
Surgically implanted |
Chronic noninfectious posterior uveitis |
Long duration and established clinical history |
| YUTIQ |
Fluocinolone acetonide |
Office-based intravitreal injection |
Chronic noninfectious posterior uveitis |
Same steroid class with less invasive administration |
| OZURDEX |
Dexamethasone |
Intravitreal applicator |
Uveitis, macular edema and retinal vein occlusion |
Broader indications and simpler administration |
| ILUVIEN |
Fluocinolone acetonide |
Intravitreal implant |
Diabetic macular edema in selected patients |
Established long-acting steroid delivery platform |
RETISERT’s main disadvantage is the requirement for surgical implantation and removal is not routine in the same way as an office injection. YUTIQ directly attacks that disadvantage. The substitution risk is highest in patients for whom the physician values long-term corticosteroid exposure but wants to avoid an operating-room procedure.
What market dynamics affect RETISERT sales?
RETISERT operates in a narrow specialty market. Demand is influenced by disease severity, steroid responsiveness, prior immunosuppressive therapy, insurance coverage and physician willingness to accept pressure and cataract risks.
Clinical segmentation
The product is most defensible in patients with:
- Severe or recurrent posterior uveitis.
- A need for durable local steroid delivery.
- Poor adherence to systemic or topical therapy.
- Contraindications to systemic immunosuppression.
- A history of responding to corticosteroids.
It is less attractive for patients who can be managed with systemic immunomodulators, biologics, shorter-acting implants or office-administered corticosteroids.
Site-of-care economics
Surgical implantation raises costs beyond the acquisition price of the implant. Providers may incur facility, surgeon, anesthesia, operating-room and postoperative-monitoring costs. YUTIQ and OZURDEX can often be administered in an office or ambulatory setting, which improves operational convenience.
The procedure also creates a reimbursement risk. A product with a higher total episode cost can lose share even if its acquisition price is competitive. Payer policies may favor office-based alternatives where clinical outcomes are considered comparable.
Safety-related utilization limits
Cataract formation and elevated intraocular pressure reduce the addressable market. These adverse effects do not eliminate steroid use, but they limit repeat treatment and encourage physicians to select patients with severe disease or limited alternatives.
What is RETISERT’s financial trajectory?
Bausch + Lomb does not report RETISERT revenue as a separate line item in its public annual reports. The product is grouped within broader ophthalmology or pharmaceutical categories, preventing a defensible product-level revenue estimate [5].
The likely trajectory is mature to declining, not growth-oriented:
| Period |
Financial interpretation |
| 2005 to early 2010s |
Launch and specialist adoption; limited indication but strong product differentiation |
| Mid-2010s |
Mature revenue base; competition from alternative steroid delivery systems increased |
| 2018 onward |
YUTIQ created direct same-active-ingredient competition with less invasive administration |
| Early 2020s onward |
Patent aging and absence of new reported indication reduced expansion potential |
| Current outlook |
Niche revenue contribution with limited visibility and low probability of material growth |
RETISERT’s revenue exposure to Bausch + Lomb is likely small relative to the company’s major ophthalmology franchises, contact-lens products and surgical businesses. The company’s public reporting does not identify RETISERT as a material standalone growth driver.
The product can still generate durable niche revenue because chronic posterior uveitis is a recurring condition and treatment decisions are specialist-led. But the market is unlikely to expand materially without a new indication, improved safety profile, easier delivery system or a commercial relaunch.
Which companies are challenging RETISERT?
The competitive set includes:
- EyePoint Pharmaceuticals, through YUTIQ.
- AbbVie, through OZURDEX following its Allergan acquisition.
- Alimera Sciences, through ILUVIEN.
- Manufacturers of systemic immunomodulators and biologics used for noninfectious uveitis.
- Potential developers of sustained-release ocular implants and suprachoroidal delivery systems.
The most direct challenge comes from EyePoint. YUTIQ preserves the long-acting fluocinolone concept while removing the need for surgical implantation. AbbVie’s OZURDEX competes through broader retinal indications and simpler administration.
RETISERT also faces indirect competition from non-implant therapies. Systemic corticosteroid-sparing treatments, including immunomodulators and biologics, can reduce repeated local steroid exposure in appropriate patients.
What generic entry risks exist for RETISERT?
Generic entry risk is technically possible but commercially uncertain. The main scenarios are:
Scenario 1: No meaningful generic entrant
A generic company may avoid RETISERT because the market is small, surgical administration is burdensome and YUTIQ already offers a differentiated alternative. This scenario preserves some branded niche revenue despite expired core patents.
Scenario 2: Complex generic or follow-on implant
A manufacturer could develop a comparable fluocinolone implant and pursue an abbreviated pathway. The product would face substantial development costs and the need to establish comparable release and clinical performance.
Scenario 3: Therapeutic substitution
The more immediate risk is not a literal RETISERT generic. It is substitution by YUTIQ, OZURDEX, systemic therapy or another long-acting ocular delivery product. Therapeutic substitution can reduce RETISERT revenue without a Paragraph IV case.
No major publicly documented Paragraph IV litigation has established a current, direct generic challenge to RETISERT as a material commercial event. The absence of prominent litigation does not eliminate technical entry risk, but it indicates that competitive pressure has been driven primarily by branded alternatives.
What patent litigation and settlements affect RETISERT?
No major active patent-litigation event involving RETISERT is publicly established as a current market-moving issue. The product’s more important legal development is the aging of its original patent estate and the shift from patent exclusivity to product differentiation.
No material settlement agreement is publicly identified as governing a major generic launch against RETISERT. YUTIQ’s entry did not depend on a conventional generic settlement because it is a separately developed branded product with a distinct delivery system and regulatory pathway.
What is the geographic coverage of RETISERT?
RETISERT’s most commercially relevant market is the United States, where it received FDA approval and where Bausch + Lomb has established ophthalmology infrastructure. International availability is more limited and varies by national approval, reimbursement and commercial distribution.
The product’s global expansion potential is constrained by:
- A narrow indication.
- Surgical administration.
- Specialist dependence.
- Local reimbursement rules.
- Competition from approved long-acting ocular products.
- The availability of systemic treatment alternatives.
The United States remains the primary market for assessing RETISERT’s commercial value, regulatory status and competitive risk.
Key Takeaways
- RETISERT is a 0.59 mg surgically implanted fluocinolone acetonide product approved in 2005 for chronic noninfectious posterior uveitis.
- Its principal commercial weakness is surgical implantation, not lack of steroid efficacy.
- YUTIQ is the closest competitor because it uses the same active ingredient and offers office-based administration.
- OZURDEX competes through a different steroid, simpler delivery and broader retinal indications.
- Core patent protection has aged, but complex implant manufacturing limits straightforward generic substitution.
- RETISERT is not subject to biosimilar competition because it is a small-molecule drug-device product.
- Bausch + Lomb does not separately disclose RETISERT revenue, preventing a reliable product-level sales estimate.
- The financial trajectory is best characterized as mature and niche, with downward pressure from therapeutic substitution.
- No major current Paragraph IV litigation or settlement is publicly established as a material RETISERT market event.
- Future value depends on specialist loyalty, reimbursement, manufacturing continuity and the absence of a high-quality generic implant.
FAQs About RETISERT Market Exclusivity and Competition
Is RETISERT still FDA approved?
Yes. RETISERT remains FDA approved for chronic noninfectious posterior uveitis involving the posterior segment of the eye [1].
Is RETISERT the same as YUTIQ?
No. Both contain fluocinolone acetonide, but RETISERT is a surgically implanted 0.59 mg device, while YUTIQ is a smaller office-administered implant with a 0.18 mg dose [1, 3].
Does RETISERT have biosimilar competition?
No. RETISERT is not a biologic. Potential competitors would use generic, follow-on or full drug-approval pathways rather than the FDA biosimilar pathway.
Why has RETISERT not been replaced by a generic?
The product combines an established drug with a sterile controlled-release implant and surgical delivery. Demonstrating equivalent release, performance and safety is more difficult than duplicating a conventional ophthalmic dosage form.
Is RETISERT a major revenue product for Bausch + Lomb?
Public filings do not identify RETISERT as a separately reported major revenue contributor. Bausch + Lomb reports broader business categories, so the product’s exact revenue and profit contribution cannot be isolated [5].
References
- U.S. Food and Drug Administration. (2005). RETISERT (fluocinolone acetonide intravitreal implant) prescribing information.
- U.S. Food and Drug Administration. (2014). ILUVIEN (fluocinolone acetonide intravitreal implant) prescribing information.
- U.S. Food and Drug Administration. (2018). YUTIQ (fluocinolone acetonide intravitreal implant) prescribing information.
- U.S. Food and Drug Administration. (2009). OZURDEX (dexamethasone intravitreal implant) prescribing information.
- Bausch + Lomb Corporation. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
